CD44 and neoplasm: In the contest of CD44-targeted antibodies, monoclonal antibody (mAb)-modified Doxil against CD44 showed a significant improvement in cellular uptake and higher doxorubicin concentration inside tumor cells than Doxil in CD44-expressing murine CRC cells [146].